• Image
  • Image
  • Image
  • Image

Angiopoietin-2 inhibition rescues arteriovenous malformation in a Smad4 HHT mouse model

Stryder Meadows, Ph.D.

Meadows Head Shot 1 2register

Assistant Professor
Stepping Stone Foundation Early Career Professor
Dept. Cell and Molecular Biology
Tulane University

Took place on March 14, 2019 at 1:00pm EST

Co-Sponsored by:                                                       CureHHT Logo Lockup RGB

Stryder Meadows -

His lab uses a combination of mouse genetics and in vitro experimental approaches to understand the basic molecular mechanisms of vascular development and disease. A main focus of the lab is to elucidate the molecular pathways associated with the vascular disorder Hereditary Hemorrhagic Telangiectasia (HHT). In particular, we aim to identify TGFb downstream targets that are involved in the formation of arteriovenous malformations (AVMs) that occur in HHT patients. We are also interested in defining the mechanisms of blood vessel fusion, as well as identifying genes with novel roles in vascular biology. Our favorite vascular model is the mouse retina, but we also investigate embryonic development.  Visit his lab's web site at https://meadowslab.squarespace.com/

Presentation - 

Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant vascular disorder caused by heterozygous, loss-of-function mutations in four TGFβ pathway members, including the central transcriptional mediator of the TGFβ pathway, Smad4. The molecular mechanisms underlying AVM pathogenesis remain poorly understood and the TGFβ pathway responsible for HHT-associated AVM formation are currently unknown. To identify potential biological targets of the TGFβ pathway involved in AVM formation, we performed RNA- and ChIP-sequencing experiments on BMP9 stimulated endothelial cells (ECs) and isolated ECs from a Smad4 inducible, EC specific knockout (Smad4-iECKO) mouse model that develops retinal AVMs. We identified the EC surface receptor, TEK (TEK receptor tyrosine kinase) and its antagonistic ligand, ANGPT2 (angiopoietin-2) as targets of Smad4. In Smad4-iECKO mice, Angpt2expression is robustly increased, while Teklevels are decreased resulting in an overall reduction in Angiopoietin-Tek signaling. Our data indicate that SMAD4 directly represses Angpt2transcription and that blockade of ANGPT2 function with monoclonal antibodies, either before or after AVMs form, prevents and ameliorates AVM formation and normalizes vessel diameters inSmad4-iECKO mice. These rescue effects are attributed to a reversion in EC morphological changes, such as size and shape. Alternative approaches that target ANGPT2 function may have therapeutic value for the improvement of HHT symptoms, such as AVMs.

The presentation will be related to 2 papers:
Vascular Deficiency of Smad4 Causes Arteriovenous Malformations: a Mouse Model of Hereditary Hemorrhagic Telangiectasia. Angiogenesis, 2018
- https://www.ncbi.nlm.nih.gov/pubmed/29460088

Angiopoietin-2 Inhibition Rescues Arteriovenous Malformation in a Smad4 Hereditary Hemorrhagic Telangiectasia Mouse Model. Circulation, accepted Jan 11, 2019.

Registration - 

Click here to register now!

All participants will be required to register. Current NAVBO members in good standing can register for free, however, the registration form must be completed.  Non-members will be charged a $25 fee for each webinar.  Once registration is complete, each registrant will receive a link and unique pin to join the meeting.  We are using GoToWebinar.  The confirmation email will include information about accessing the webinar.

If you have any questions, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.